Global Genomics Group (G3) Completes Patient Enrollment of Discovery Cohort in Global Study Ahead of Schedule

RICHMOND, Va., Feb. 13, 2014 /PRNewswire/ — Global Genomics Group (G3) today announced that it has completed enrollment of the 5,000-patient discovery cohort of its GLOBAL (Genetic LOci and Burden ofAtherosclerotic Lesions) clinical study. Pilot data for the first cohort of patients are expected later this year.

Read the full article here:

Global genomics group (g3) completes patient enrollment of discovery cohort in global study ahead of schedule